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BACKGROUND: Preoperative PSA, ISUP grade group (GG), prostate examination and multiparametric MRI (mpMRI) form the basis of
prostate cancer staging. Unlike other solid organ tumours, tumour volume (TV) is not routinely used aside from crude estimates
such as maximum cancer core length. The aim of this study is to assess the role of TV as a marker for oncological outcomes in highrisk non-metastatic prostate cancer.
METHODS: A prospectively maintained database of patients undergoing minimally invasive (laparoscopic or robot-assisted
laparoscopic) radical prostatectomy at a UK centre between 2007 and 2019 were analysed. A total of 251 patients with NCCN high
or very high-risk prostate cancer were identiﬁed. Primary outcome measure was time to biochemical recurrence (BCR) and the
secondary outcome was time to treatment failure (TTF). TV was measured on the pathological specimen using the stacking method.
Multivariable cox regression analysis was used to identify factors predicting BCR and TFF. TV as a predictor of BCR and TFF was
further analysed through time-dependent receiver operating characteristic (ROC) curves. Kaplan–Meier survival estimates were
used to evaluate TV cut-off scores.
RESULTS: Median follow up was 4.50 years. Four factors were associated with BCR and TFF on multivariable analysis (TV,
pathological GG, pathological T stage, positive margin >3 mm). Area under the Curve (AUC) for TV as a predictor of BCR and TTF at 5
years was 0.71 and 0.75, respectively. Including all 4 variables in the model increased AUC to 0.84 and 0.85 for BCR and TFF. A
2.50 cm TV cut off demonstrated a signiﬁcance difference in time to BCR, p < 0.001.
CONCLUSIONS: Pathological tumour volume is an independent predictor of oncological outcomes in high risk prostate cancer but
does not add signiﬁcant prognostic value when combined with established variables. However, the option of accurate TV
measurement on mpMRI raises the possibility of using TV as useful marker for preoperative risk stratiﬁcation.
Prostate Cancer and Prostatic Diseases; https://doi.org/10.1038/s41391-021-00468-4

INTRODUCTION
Staging and planning of radical prostatectomy is based on
preoperative PSA, ISUP grade group, prostate examination and
multiparametric MRI (mpMRI). Just as the use of mpMRI
improved diagnostic accuracy, it reﬁned prostate cancer staging.
While this undoubtedly reduced staging errors and improved
selection for nerve-sparing techniques its full potential for preand post-operative prognostication has not yet been harnessed.
Important staging parameters such as extracapsular extension
and seminal vesicle invasion form the basis of various prognostic
classiﬁcations in addition to PSA, GG and biopsy information [1].
Tumour volume is a parameter that features in many pre- and
post-operative staging classiﬁcations for solid organ cancers
including breast, testis and kidney. In prostate cancer only crude
pre-operative surrogates of pathological tumour volume like

maximum cancer core length or percentage of positive biopsy
cores have been used. Indeed, despite the utility of mpMRI, it is
not recognised in staging schema. Hitherto, tumour volume as
the simplest ﬁrst degree radiomic feature was difﬁcult to
measure on staging mpMRI. This is now being revisited. Use of
machine learning approaches in addition to radiomics analysis
has led to the successful segmentation of the prostate offering
the possibility of TV as one of the simplest ﬁrst degree radiomic
features for use as a prognostic parameter [2]. In this context we
ﬁrstly explore the correlation of pathological tumour volume
with oncological outcome [3].
In prostate cancer, Stamey et al. ﬁrst demonstrated that TV was
a possible predictor for capsular penetration, seminal vesicle
invasion and metastatic disease [4]. Subsequent studies have
focussed on using TV to identify insigniﬁcant prostate cancers
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with very few studies including high-risk tumours. Classically a cut
off volume of 0.50 cm3 has been used to classify clinically
insigniﬁcant cancer [5, 6].
If size reﬂects biological potential, we hypothesize that TV as
measured on a pathological specimen adds important information
on tumour biology and aids classiﬁcation and planning of
treatment [7]. This study aims to assess the role of TV as a marker
for cancer recurrence in high-risk non-metastatic prostate cancer.
It is thus considered as the initial experimental step towards using
segmented TV combined with other radiomic features on mpMRI
as a prognostic staging parameter.
Subjects and methods
We analysed a prospectively maintained database of patients
undergoing minimally invasive (laparoscopic or robot assisted
laparoscopic) radical prostatectomy at a tertiary UK referral
centre between 2007 and 2019. All patients with NCCN high-risk
or very high-risk (forthwith termed high-risk) prostate cancer
were identiﬁed. Only patients with complete information on
ISUP grade group (GG), PSA, tumour stage, TV and outcome data
were included. TV was calculated from the ﬁnal pathological
specimen using the stacking method which provides an
accurate three-dimensional reconstruction of the tumour and
cubic tumour volume [8]. For multifocal tumours, the total
aggregate volume was reported. All patients underwent DRE,
PSA, prostate MRI and prostate biopsy according to practice at
the time (transrectal ultrasound guided, transperineal template
ultrasound guided or MRI targeted transperineal ultrasound
guided). Patients were excluded if they had evidence of pelvic
lymph node or metastatic disease on preoperative evaluation.
Patients undergoing salvage prostatectomy following radiotherapy or focal therapy were excluded.
Follow up included PSA at least every 6 months for 2 years and
annually thereafter. The primary outcome measure was time to
biochemical recurrence (BCR) from the date of radical prostatectomy. BCR was deﬁned as a PSA rise above 0.20 ng/ml or physician
deﬁned (three consecutive PSA rises above nadir). The secondary
outcome measure was Time to Treatment Failure (TTF) from the
date of radical prostatectomy. Treatment failure was deﬁned as
the use of any form of salvage or palliative treatment, occurrence
of local recurrence or distant metastasis as diagnosed on imaging.
There were no deaths attributable to prostate cancer without
preceding BCR and adjuvant or salvage treatment.
Statistical analysis
Data were shown to have non-Gaussian distributions and nonparametric analyses were performed. Medians and interquartile
ranges were reported for continuous variables.
Multivariable Cox regression analyses were performed to
predict BCR and TFF free survival. A model was constructed
a-priori containing TV in addition to the principles variables
predicting oncological outcomes based on current literature and
agreed by the study authors [9]. Included variables were
pathological GG, pathogical T stage, presenting PSA, age, margin
status (positive >3 mm), Charlson Comorbidity score and TV.
Signiﬁcance was set at p < 0.050.
The diagnostic capability of TV was analysed through timedependent receiver operating characteristic (ROC) curves with a
Kaplan–Meier estimate of time. Censored survival data was plotted
using the survivalROC package for R (R Core Team 2020. R: A
language and environment for statistical computing. R Foundation
for Statistical Computing, Vienna, Austria) [10]. ROC curves were
plotted for TV alone and for all variables in the ﬁnal multivariable
Cox’s proportional hazards regression model. To accommodate
multiple covariates, a ﬁtted linear predictor from the Cox model
was used to construct the ROC curve [11].
Area under the Curve (AUC) was used to assess the overall
diagnostic accuracy of TV. Youden’s index was used to identify the

optimum cut-off. TV cut off values were compared used the
Kaplan–Meier estimate with a log rank test for time to BCR and
treatment failure. All other statistical analyses were performed
using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics for
Windows, Version 25.0. Armonk, NY: IBM Corp).
RESULTS
A total of 685 patients underwent minimally invasive radical
prostatectomy and met the inclusion criteria for the study: 251
patients had high-risk prostate cancer. Patient demographic,
clinical and tumour characteristics for high-risk and non-highrisk populations are reported in Table 1. Median follow up in the
high-risk cohort was 4.50 years and 45% (n = 112) of patients
had over 5 years follow up. Aside from tumour features, clinical
and demographic details for patients with and without high-risk
prostate cancer were equivalent. TV were signiﬁcantly greater
in high-risk than non-high-risk patients despite equal overall
specimen sizes. 14 patients died during follow up.
Following multivariable analysis predicting BCR and TFF using
a model containing seven predictors as described above, four

Table 1. Demographic and clinical characteristics of patients with
high-risk and non high-risk prostate cancer.
Parameter
Total Patients (n)

High risk
prostate cancer
251

Non high-risk
prostate cancer

P value

434

Median Age (IQR)

63.00 (8.20)

62.90 (8.60)

0.290

Median PSA (IQR)

11.90 (12.00)

8.00 (4.56)

<0.001

Mean Charlson
Comorbidity
Index (IQR)

0 (1)

0 (1)

0.812

Median Tumour
Volume (IQR)

3.60 (5.45)

1.93 (2.55)

<0.0001

232.00 (310.00)

258.50 (275.70)

0.372

41.00 (21.00)

40.00 (19.00)

0.144

19 (4.38%)

<0.001

<0.001

Median No. of
Weeks followUp (IQR)
Median Specimen
Size (IQR)
Patients with
Neoadjuvant
Treatment (ADT
and/or
Radiotherapy) (%)

63 (25.10%)

Pathological Grade Group, n (%)
1

7 (2.79)

70 (16.13)

2

104 (41.43)

280 (64.52)

3

86 (34.26)

75 (17.28)

4

12 (4.78)

4 (0.92)

5

42 (16.73)

5 (1.15)

Pathological T Stage, n (%)
T2a

12 (4.78)

17 (3.933)

T2b

3 (1.20)

8 (1.85)

<0.001

T2c

64 (25.50)

258 (59.58)

T3a

113 (45.02)

114 (26.33)

T3b

54 (21.51)

32 (7.39)

T4

5 (1.99)

4 (0.92)

Biochemical
Recurrence, n (%)

137 (54.58)

147 (33.87)

<0.001

Failure Free
Survival, n (%)

132 (52.59)

314 (72.35)

<0.001
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Table 2.

Multivariable analyses of factors predicting BCR and TTF in patients with high-risk prostate cancer.

Covariate

Multivariable analysis for time to BCR
Hazard Ratio (95% CI)

p value

Multivariable analysis for time to TFF
Hazard Ratio (95% CI)

p value

Age

0.98 (0.95–1.02)

0.322

0.99 (0.95–1.02)

0.411

PSA

0.99 (0.97–1.00)

0.117

0.98 (0.96–1.00)

0.100

Tumour Volume

1.06 (1.03–1.10)

<0.001

1.07 (1.03–1.11)

<0.001

reference

n/a

Pathological Grade Group
Grade Group 1

0.03

n/a
reference

0.018
n/a

Grade Group 2

1.96 (0.47–8.28)

0.358

2.62 (0.35–19.47)

0.345

Grade Group 3

2.37 (0.56–10.11)

0.242

3.42 (0.46–25.61)

0.229

Grade Group 4

4.19 (0.83–21.31)

0.084

5.24 (0.57–47.80)

0.142

Grade Group 5

4.02 (0.93–17.48)

0.063

6.16 (0.81–46.71)

0.079

Pathological T Stage

0.01

T2a

reference

T2b

2.43 (0.21–27.50)

n/a
0.475

n/a
reference
3.45 (0.24–49.49)

0.01
n/a
0.362

T2c

1.77 (0.50–6.22)

0.374

1.90 (0.41–8.69)

0.412

T3a

4.17 (1.24–14.02)

0.021

5.39 (1.25–23.28)

0.024

T3b

5.33 (1.58–18.04)

0.007

6.92 (1.60–30.01)

0.010

T4

9.54 (1.83–49.70)

0.007

10.55 (1.69–65.85)

0.012

Positive Margin Length > 3 mm

1.86 (1.18–2.91)

0.007

1.82 (1.14–2.94)

0.013

Charlson Comorbidity Index

1.10 (0.89–1.36)

0.378

1.13 (0.91–1.42)

0.269

Fig. 2 ROC curves for tumour volume and combined variables
predicting TTF. ROC curves for tumour volume and all 4 signﬁcant
variables predicting TTF at 5 years in patients with high-risk prostate
cancer.

Fig. 1 ROC curves for tumour volume and combined variables
predicting BCR. ROC curves for tumour volume and all 4 signﬁcant
variables predicting BCR at 5 years in patients with high-risk prostate
cancer.

variables remained signiﬁcant for predicting both BCR and TFF
(Table 2). These were TV, pGG, pT and positive margin >3.00 mm.
ROC curves were plotted for TV alone and the four signiﬁcant
predictor variables using censored outcome data for BCR and TTF.
When modelled over time, area under the curve (AUC) values for
the prediction of both BCR and TTF peaked at 5 years. TV alone as
a predictor for BCR at 5 years was 0.71 (Fig. 1). Including all
signiﬁcant variables as covariates increased the AUC to 0.84. The
cut-off value (point of maximum TP and 1-FP) was 2.50 cm.
For TTF AUC for TV volume alone at 5 years was 0.75 and 0.85
when all variables were included in the model (Fig. 2). TV alone
resulted in a cut off value of 2.54 cm.
Despite a reduction in data points, modelling of outcomes at 10
years mirrored these results albeit with reductions in the AUC.
Prostate Cancer and Prostatic Diseases

AUC for TV alone and all variables was as a predictor for BCR 0.64
and 0.80, respectively (Supplementary Figs. 1 & 2). Likewise, AUC
for prediction of TTF at 10 years was 0.72 and 0.83, respectively
(Supplementary Figs. 3 & 4).
A further comparison of the model with and without TV was
undertaken. A model containing using the three variables pGG, pT
and margins >3 mm status had a AUC of 0.838 in comparison to
the full model containing all 4 variables with an AUC of 0.843.
Kaplan–Meier estimates were plotted using a 2.50 cm TV cut off
for BCR (Fig. 3). Log rank test demonstrated survival distributions
were signiﬁcantly different for BCR, p < 0.001.
DISCUSSION
This study demonstrates that TV measured in histopathological
specimens is signiﬁcantly associated with oncological outcomes
following radical prostatectomy for high risk prostate cancer.
However, its prognostic value when combined with known
predictive variables such as pGG, pT stage and margin status is
limited.
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Fig. 3 Kaplan–Meier curves for BCR-free survival. Kaplan–Meier
curves for BCR-free survival stratiﬁed by tumour volume.

Whilst risk stratiﬁcation tools for identifying low, intermediate
and high-risk disease are common, exact deﬁnitions for high-risk
disease are debated and outcomes may vary considerably. In
certain patients, radical prostatectomy can effectively treat highrisk disease with high metastasis-free and cancer speciﬁc survival
rates [12]. Various attempts have been made to identify factors
that may predict outcomes in high-risk localised prostate cancer.
Historically criteria set by D’Amico have been widely used
although it is increasingly recognised that especially for high-risk
patients, the categories may be too broad. Further systems have
been promoted such as the NCCN classiﬁcation used in this study.
The aim of all such systems is accurately predict a speciﬁc patient’s
treatment speciﬁc prognosis. In order to do so, they mostly
incorporate all available prognostic information.
Various studies have reﬁned the predictions offered by these
standard models. Further subdivision of high-risk patients using the
existing parameters of T stage, PSA and GG has been shown to be
predict BCR and survival [13, 14]. Other studies have recommended
the use of other factors such as PSAD or percentage of positive
cores [15, 16]. These approaches come with a number of limitations.
Accurate diagnosis in prostate cancer remains a considerable
challenge despite advances in imaging modalities and biopsy
technique. Previous studies have shown that even in high-risk
prostate cancer, grade group may change in almost 50% of patients
on ﬁnal histology [17]. Results from our study reﬂect this
uncertainty. With long-term follow up data, no preoperative factors
accurately predicted either BCR or failure free survival on regression
analysis. This discrepancy is likely due to the select high-risk cohort
of patients.
The role of TV as a prognostic marker in prostate cancer has
been assessed previously. To date TV has primarily been
considered in the context of differentiating low risk signiﬁcant
and insigniﬁcant cancer in the preoperative setting. Correlation
between post-operative TV and both other tumour parameters
and oncological outcomes have been shown. Studies have
demonstrated associations with PSA, Gleason grade and capsular
penetration [18–20]. Likewise, post-operative TV has been shown
to independently predict BCR [21–25]. Interestingly Merrill et al.
found no associations for low grade tumours. These results
support our ﬁnding that tumour size may predict prognosis
alongside margin status, pT and pGG. Hong et al similarly found
TV to be accurate predictor of PSA recurrence in high-risk prostate
cancer albeit using arbitrary cut off values [26]. The interactions

between TV and other pathological factors needs further
exploration: is TV a surrogate marker for tumour stage and/or
grade [27]? Overlapping predictive outcomes for TV and T stage in
this study together with the limited additional prognostic value
supports this hypothesis. Previous debate over the role of TV has
been driven by a number of studies showing no correlation with
outcomes [28–31]. The current study does support a possible role
for TV although further work on its application is required.
Limitations to the current study need to be considered. The
potential bias intrinsic to single centre retrospective analyses
needs to be acknowledged. Inconsistencies in TV measure may
also be relevant. Unsurprisingly computed planimetry has been
shown to yield better associations than visual estimation methods
[26]. Yet both total TV and volume of the primary lesion alone
have been shown to be directly correlated [7]. Finally, our cohort
of patients underwent heterogenous investigation protocols
reﬂective of the developments in prostate cancer diagnostics.
Potentially these may have contaminated the analysis of the
preoperative investigations. Follow up to 10 years was also
reduced however analysis shows evidence that the models offer
consistent results in the very long term.
This study aimed to evaluate the role of TV for risk
stratiﬁcation in high-risk prostate cancer. Survival analysis has
shown that TV has a prognostic value, but does not offer
additional information in addition to pGG and pT stage. Of note
TV was measured from the histopathalogical specimen; ongoing
advances in imaging offer the possibility of accurately measuring TV preoperatively. TV measured on preoperative mpMRI has
been shown to correlate with postoperative histological specimens although current techniques are limited by tendency to
underestimate size. Even TRUS has been shown to predict TV
and soon we believe that advances in prostate MRI incorporating radiomics analysis and machine learning methods offer the
potential for accurate preoperative TV segmentation [2, 32, 33].
Consequently, TV may emerge as an accurate pre-operative
marker for prognostication and risk stratiﬁcation alongside
prostate biopsy and other current tools.
CONCLUSIONS
We conclude that reasonable experimental evidence of measured
pathological TV as independent oncological prognosticator exists
in this cohort of patients despite the limited value over existing
markers. Our results support the following working hypothesis for
future studies: segmented TV from preoperative mpMRI scans
correlates with pathological TV and independently predicts
oncological outcome.
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